WHEL-C-078 · Moderate evidence · 6/10

inositol for PCOS

A systematic review/meta-analysis informing the 2023 PCOS guidelines found the evidence for inositol in PCOS limited and inconclusive, with efficacy indeterminate, though one comparison review described it as useful for endocrine-metabolic disorders.

Origin · Existing drug · repurposing candidatePathway · 505(b)(2) · existing active ingredient, new indicationEvidence arm · Direct researchEvidence supports

How to read thisThe summary above and the proposed mechanism are generated by the model from the sources it ingested, and are written as the model’s reasoning rather than established fact. Any figure quoted from MATRIX is a model-derived association score, not a clinical measurement. How far the published record backs this pair is carried by the score’s own rigor dimension and traced to verbatim sources at the foot of the page.

Hypothesized mechanism

Inositol may act as an insulin sensitizer to counter the endocrine-metabolic disturbances of PCOS.

This is the model’s proposed mechanism from the sources on file, not a demonstrated causal pathway. How well the published record supports it is reflected in the rigor and plausibility dimensions of the score, and traced to the verbatim sources at the foot of the page.

How the score was reached, for this pair

The composite score is the sum of five dimensions, each scored 0 to 2 by the model from the evidence on file. Below is the sub-score this specific pair received on each, with what that dimension measures. It scored 6 of 10 overall, a moderate reading, from a direct rated moderate in strength.

The model’s overall reasoning for this pair is the summary at the top of the page, and the mechanism it proposed is in the section above.

Direct research arm · anchors the headline6.0 / 10 · Moderate

Scored for women. Evidence generated in women (female population, ~100% female). (band F1, ×1.00).

Corroboration

Evidence comes from a systematic review/meta-analysis informing the 2023 PCOS guidelines (claims 1-3), which counts as a single synthesis (score 1, not independent replication). Claim 4 is from a separate review but is non-quantitative; the dominant high-quality source is one meta-analysis.

1 / 2

Rigor

The primary source is a systematic review and meta-analysis (claims 1-3) used to inform international evidence-based guidelines, which qualifies as the highest rigor tier. Claim 4 is from a comparison/review article.

2 / 2

Specificity

Both inositol and PCOS are named directly in all claims (e.g., 'inositol in the management of PCOS'). The intervention and condition are unambiguous.

2 / 2

Plausibility

Claim 4 asserts inositol counters 'the endocrine-metabolic disorders' of PCOS, implying an insulin-sensitizing/metabolic mechanism, but this is asserted rather than mechanistically evidenced in the quotes. No molecular mechanism data is presented.

1 / 2

Consistency

The sources directly conflict: the meta-analysis finds efficacy 'indeterminate,' 'limited and inconclusive,' and 'may have no effect' (claims 1-3), while claim 4 calls inositol 'useful.' Results disagree in direction.

0 / 2

How the scoring rubric works, in general →

Layers not covered for this pair

Sex-specific pharmacokineticsNone on file

Not covered for this pair. This layer holds documented sex-specific pharmacokinetics for a limited set of drugs, and this compound is not among them yet. A blank here means the drug is not covered by the layer, not that no sex difference exists.

More on the sex-specific pharmacokinetics layer and its sources →

Cycle-phase dependenceNone on file

Not covered for this pair. The cycle-phase layer is seeded for the strongest-evidence cases so far (PMDD), and this pair is not among them yet. A blank here means the pair is not covered by the layer, not that the effect was found to be phase-independent.

More on the cycle-phase layer and its sources →

Source evidence · what the pipeline ingested

These are the sources the pipeline ingested to detect and score this signal, the published literature the model actually read, each tagged by study type. Where the model combined findings the claim is marked as a synthesis (S), and where the literature disagrees the contradiction is shown (!).

Every source below belongs to this signal’s evidence arm, Direct research. Whel reads each drug-condition pair through four such arms, each held to its own inclusion bar; a signal is surfaced through one of them.

1its efficacy in the management of PCOS remains indeterminate PubMed · PMID 38163998 ↗
2The evidence supporting the use of inositol in the management of PCOS is limited and inconclusive. PubMed · PMID 38163998 ↗
3inositol may have no effect on other outcomes PubMed · PMID 38163998 ↗
4the introduction of inositol in the treatment plan has proved to be as reasonable as useful in countering the endocrine-metabolic disorders of this syndrome PubMed · PMID 25670222 ↗

These are the verbatim sources the pipeline surfaced and read; they may not be the full published record for a pair, and the score reflects the strength and agreement of the evidence rather than its volume. The strength of these source types is what the rigor dimension of the score reads off. MATRIX, sex-specific pharmacokinetics, and cycle phase are separate layers the pipeline does not ingest, external cross-references reported beside the score, and they link to their own sources in their sections above.

The primary sources and pipelines this evidence is drawn from →

← Back to the full index